Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol

BACKGROUND: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. Hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Avallone, Antonio, Piccirillo, Maria Carmela, Di Gennaro, Elena, Romano, Carmela, Calabrese, Filomena, Roca, Maria Serena, Tatangelo, Fabiana, Granata, Vincenza, Cassata, Antonio, Cavalcanti, Ernesta, Maurea, Nicola, Maiolino, Piera, Silvestro, Lucrezia, De Stefano, Alfonso, Giuliani, Francesco, Rosati, Gerardo, Tamburini, Emiliano, Aprea, Pasquale, Vicario, Valeria, Nappi, Anna, Vitagliano, Carlo, Casaretti, Rossana, Leone, Alessandra, Petrillo, Antonella, Botti, Gerardo, Delrio, Paolo, Izzo, Francesco, Perrone, Francesco, Budillon, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425244/
https://www.ncbi.nlm.nih.gov/pubmed/32849914
http://dx.doi.org/10.1177/1758835920929589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425244/
https://www.ncbi.nlm.nih.gov/pubmed/32849914
http://dx.doi.org/10.1177/1758835920929589

Ejemplares similares